{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.69","upperLimit":"0.96","value":"0.89"},{"groupId":"OG001","lowerLimit":"0.83","upperLimit":"0.90","value":"0.87"},{"groupId":"OG002","lowerLimit":"0.80","upperLimit":"0.87","value":"0.84"},{"groupId":"OG003","lowerLimit":"0.83","upperLimit":"0.89","value":"0.87"},{"groupId":"OG004","lowerLimit":"0.51","upperLimit":"0.82","value":"0.70"},{"groupId":"OG005","lowerLimit":"0.71","upperLimit":"0.85","value":"0.79"},{"groupId":"OG006","lowerLimit":"0.66","upperLimit":"0.80","value":"0.74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"380"},{"groupId":"OG002","value":"382"},{"groupId":"OG003","value":"571"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"153"},{"groupId":"OG006","value":"152"}],"units":"Participants"}],"description":"Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients-off therapy before callback-Induction only","id":"OG000","title":"Arm I (Patients Off-therapy Before Callback-Induction Only)"},{"description":"RER with Complete Response - IFRT (Standard Arm)","id":"OG001","title":"Arm II (RER With CR [ABVE-PC, IFRT])"},{"description":"RER with Complete Response - no IFRT (Reduced Therapy Arm)","id":"OG002","title":"Arm III (RER With CR [ABVE-PC])"},{"description":"RER with less than Complete Response - IFRT","id":"OG003","title":"Arm IV (RER With Less Than CR [ABVE-PC, IFRT])"},{"description":"RER with Progressive Disease - Off Therapy","id":"OG004","title":"Arm V (RER With PD)"},{"description":"SER - randomized to DECAX2 + ABVE-PCX2 + IFRT","id":"OG005","title":"Arm VI (SER [DECA, ABVE-PC, IFRT])"},{"description":"SER - randomized to ABVE-PCX2 + IFRT","id":"OG006","title":"Arm VII (SER [ABVE-PC, IFRT])"}],"paramType":"NUMBER","populationDescription":"Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).","reportingStatus":"POSTED","timeFrame":"5 years","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"Probability of survival"}